Baxter Healthcare Corp. will temporarily import from the United Kingdom certain amino acid drugs in short supply in the United States, beginning with limited quantities in the next few weeks, the Food and Drug Administration announced last week. In other news, FDA last week released draft guidance aimed at making it easier for brand and generic drug companies to implement a shared risk evaluation and mitigation strategy. FDA can require drugs associated with serious risks to implement a REMS with elements to assure safe use. In such cases, current law requires brand and generic drug companies to try to reach agreement on a shared system REMS. “As we work to make it easier to engage in a shared system REMS, we’ll be looking more specifically at how we can address situations where innovator firms may be leveraging the single, shared system REMS requirement to block or delay generic competition,” said FDA Commissioner Scott Gottlieb, M.D. The agency will accept comments on the draft guidance through Jan. 8.

Related News Articles

Headline
The Centers for Disease Control and Prevention this week announced an anticipated shortage of Aplisol, one of two TB skin tests licensed by the Food and Drug…
Headline
A federal court in Texas yesterday ordered Pharm D Solutions to stop producing or distributing compounded drugs intended to be sterile until the company…
Headline
The Food and Drug Administration Friday issued final guidance clarifying how sponsors may show that a proposed biosimilar product is interchangeable with a…
Headline
The House Judiciary Committee yesterday approved by voice vote the Creating and Restoring Equal Access to Equivalent Samples Act (H.R. 965).
Headline
Civica Rx, the not-for-profit generic drug company, officially opened its headquarters last week in Lehi, Utah.
Headline
The Food and Drug Administration plans to revise its 2016 draft compounding guidance for hospital and health system pharmacies.